Yong Lian, Ph.D
Editor-in-Chief, Environmental Medicine, Molecular Biochemistry and Pharmacology
New York University School of Medicine, New York, China
He is now a doctor of the First Affiliated Hospital of Wenzhou Medical University. Young Visiting Scholar, Department of Environmental Medicine, Molecular Biochemistry and Pharmacology, New York University School of Medicine.
15 NIH RO1 and PPG research projects totaling more than $25 million;
It has been funded by five key projects of international Cooperation and exchange of the National Natural Science Foundation of China.
Related carcinogenic molecular mechanisms of environmental carcinogens, tumor invasion and metastasis mechanisms, and screening and identification of novel antitumor agents and their anti-tumor molecular mechanisms.
Director, Settlement Clinic
Shouji Shimoyama is serving as Director of Settlement Clinic Tokyo. He has published 50 more research articles.
Professor and Chair, Department of Pharmaceutical Sciences
University of South Florida, USA
Dr. Zhou is a professor in the School of Health Sciences at the Royal Melbourne Institute of Technology RMIT University in Australia. Having originally studied and practiced clinical medicine in China he undertook his PhD in pharmacology at the University of Auckland, New Zealand and has also worked at the National University of Singapore and the Queensland University of Technology. He is currently affiliated with the WHO Collaborating Center for Traditional Medicine. Professor Zhou is the editor of Drug Metabolism Letters and acts as a guest editor for Current Pharmaceutical Design and Current Drug Metabolism. In addition he is an Associate Editor or Editorial Board Member of several other international journals including Current Drug Therapy the Open Journal of Drug Metabolism and Therapeutics and Clinical Risk Management. He is a reviewer for dozens of international scientific journals including Drug Safety the International Journal of Pharmaceutics, the Journal of Pharmacy and Pharmacology, the Lancet and Pharmacology and Therapeutics. In 2005 he was the recipient of the Research Excellence Award at the Pharmacy Honors Day from the National University of Singapore, Department of Pharmacy. He currently has published over 220 refereed journal papers with more than 1400 citations.
Professor Zhou's major research interests include pharmacokinetics, Pharmacogenetics, evaluation of herbal medicines and drug delivery.
Assistant Professor, Department of Pharmacology
University of Athens Medical School, Greece
Dr. Despina Sanoudou is an Assistant Professor at the Pharmacology Department- Medical School, University of Athens. She studied Molecular Biology, obtained a PhD at the University of Cambridge, got certified in Clinical Molecular Diagnostics (American Board of Medical Genetics), and served as Instructor at the Harvard Medical School and the Children’s Hospital of Boston. Her research team focuses on the discovery of novel diagnostic and prognostic markers, the identification of novel therapeutic targets, and the evaluation of chemical compounds against cardiovascular and neuromuscular diseases. The results of this work have been published in over 70 scientific articles and book chapters, 145 oral and 170 written presentations in scientific meetings worldwide. She serves as an evaluator of research grant applications at the European Commission and other international organizations, as an Editorial Board member of 7 publishers, and as a reviewer in 20 scientific journals. Furthermore, she teaches at 9 MSc programs and has founded the first High School Outreach Program in Greece, which has hosted 2,000 students to date. Dr Sanoudou has received a series of awards including the L’Oreal-UNESCO award for Young Women in Science, an American Society of Human Genetics education award, multiple Hellenic Cardiological Society and Greek Society of Pharmacology scientific awards and others.
Pharmacogenomics in Cardiovascular and Neuromuscular Disease, with an Emphasis on Identifying Novel Therapeutic Targets and Evaluating the Molecular Effects of Novel Therapeutic Compounds.
Jinwei Zhang, PhD
Associated Professor, Medicine and Health
The Business School University of Exeter, United Kingdom
Dr Jinwei Zhang is an Associated Professor at the University of Exeter Medical School, UK; Research Professor at Xiamen University China, Visiting Fellow at Yale School of Medicine US. His laboratory studies ion channels, transporters, and signalling pathways that associated with human diseases, for examples, stroke that regulated by WNK-SPAK/OSR1-KCC2/NKCC1, hypertension that regulated by WNK-SPAK/OSR1-NCC, and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules, CRISPR/Cas9 gene-editing technologies, and electrophysiology to aid discovery and validation of new potential drug targets. He is internationally recognized for his expertise in cellular chloride homeostasis and cell volume regulation and drug discovery. He has published more than 70 articles in journals including Nature Medicine, Cell Metabolism, Neuron, Nature Communications, EMBO molecular medicine, Science Signalling, Human Molecular Genetics etc. and has achieved more than 2420 citations, H-index=28.. He is an Associate Editor for the Frontiers in Pharmacology, and Frontiers in Physiology. He is currently a member of the editorial boards of 15 scientific journals, as well as a reviewer for more than 40 scientific journals.
His laboratory studies ion channels, transporters, and signalling pathways that associated with human diseases, for examples, stroke that regulated by WNK-SPAK/OSR1-KCC2/NKCC1, hypertension that regulated by WNK-SPAK/OSR1-NCC, and concern with elucidating and targeting ion transporters, kinases, protein-protein interactions using genetic mouse models, small molecules, CRISPR/Cas9 gene-editing technologies, and electrophysiology to aid discovery and validation of new potential drug targets.